[{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SBT101","moa":"ALDP expression","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Purespring Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"SwanBio Therapeutics \/ SwanBio Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"SwanBio Therapeutics \/ SwanBio Therapeutics"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SBT101","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"SwanBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SwanBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SBT101","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SwanBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SwanBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SwanBio Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by SwanBio Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was also shown to be well-tolerated in non-human primates through six months post-treatment.

                          Brand Name : SBT101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 04, 2023

                          Lead Product(s) : SBT101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy. In preclinical studies, SBT101 demonstrated dose-dependent improvement of disease markers and functional improvement in AM...

                          Brand Name : SBT101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          December 15, 2022

                          Lead Product(s) : SBT101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have an option to develop any targets identified and to own and commercialise any ...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 18, 2022

                          Lead Product(s) : AAV-based Gene Therapy

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Recipient : Purespring Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : SBT101 is first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was designed to compensate for the disease-causing ABCD1 mutation.

                          Brand Name : SBT101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 27, 2022

                          Lead Product(s) : SBT101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : SwanBio’s latest round of financing will support the ongoing evolution into a fully integrated research and development organization, with an initial focus on the clinical advancement of SBT101, including plans to dose patients in a Phase 1/2 trial.

                          Brand Name : SBT101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 18, 2022

                          Lead Product(s) : SBT101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Syncona Limited

                          Deal Size : $56.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : In all mouse model and NHP studies, IT administration of SBT101 was well tolerated at doses predicted to be clinically relevant in people with AMN, and no drug-associated adverse events were noted.

                          Brand Name : SBT101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 17, 2022

                          Lead Product(s) : SBT101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank